Search - tctmd.com

Displaying 761 - 780 of 2437

Sort: Relevancy | Date

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

April 23, 2020

In the Setting of PFO, Time to Retire ‘Cryptogenic’ Stroke

News Daily News

In the Setting of PFO, Time to Retire ‘Cryptogenic’ Stroke

Yael L. Maxwell

April 16, 2020

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

News Daily News

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

April 10, 2020

CABG Over PCI for Severe HFrEF Patients With Complex CAD: Observational Data

News Daily News

CABG Over PCI for Severe HFrEF Patients With Complex CAD: Observational Data

April 09, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

News Conference News ACC 2020

Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO

Michael O'Riordan

March 31, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

March 29, 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.